C86.0 Extranodal NK/T-cell lymphoma, nasal type

Name of the Condition

• Extranodal NK/T-cell lymphoma, nasal type
• ICD-10 Code: C86.0

Summary

Extranodal NK/T-cell lymphoma, nasal type is a rare type of non-Hodgkin lymphoma that primarily affects tissues outside the lymph nodes, most commonly the nasal cavity and paranasal sinuses. It originates from natural killer (NK) cells or T-cells and may involve other extranodal sites such as the skin, gastrointestinal tract, or soft tissues. The disease can progress locally or spread to distant sites if left untreated.

Causes

The exact cause involves genetic mutations in NK or T-cells leading to uncontrolled proliferation. Epstein-Barr virus (EBV) infection is frequently associated with this condition, particularly in nasal and other extranodal sites. Immune system dysregulation and environmental factors may also contribute to its development.

Risk Factors

• Epstein-Barr virus (EBV) infection
• Immunosuppression (e.g., from medications or HIV)
• Asian or South American ethnic background
• Male gender
• Prior exposure to certain chemicals or radiation
• Advanced age

Symptoms

• Persistent nasal obstruction or congestion
• Nosebleeds or facial pain
• Ulceration or necrosis in the nasal cavity
• Swollen lymph nodes in the neck
• Skin lesions or rashes (if skin involvement)
• Fever, night sweats, or unexplained weight loss
• Abdominal pain or bleeding (if gastrointestinal involvement)

Diagnosis

Diagnosis involves a physical examination, followed by biopsy of affected tissue to confirm lymphoma type and EBV association. Imaging (CT, MRI, or PET) assesses disease extent, and blood tests evaluate cell counts and organ function. Flow cytometry and immunohistochemistry help identify NK/T-cell markers.

Treatment Options

Treatment typically includes chemotherapy, often with regimens targeting NK/T-cell lymphomas. Radiation therapy may be used for localized nasal disease. Stem cell transplantation or clinical trials may be considered for advanced or refractory cases. Supportive care addresses symptoms and complications.

Prognosis and Follow-Up

Prognosis varies based on disease stage, location, and response to treatment. Early-stage nasal disease may have better outcomes with combined therapy. Regular follow-up with imaging and clinical assessments monitors for recurrence or progression. Long-term surveillance is recommended due to potential late effects.

Complications

• Local tissue destruction (e.g., nasal perforation)
• Spread to other organs (e.g., skin, lungs, gastrointestinal tract)
• Infection due to immunosuppression
• Treatment-related toxicities (e.g., chemotherapy side effects)
• Secondary malignancies

Lifestyle & Prevention

• Avoid known environmental risk factors (e.g., certain chemicals)
• Maintain overall immune health
• Seek prompt evaluation for persistent nasal symptoms
• Follow recommended cancer screening guidelines if high risk

When to Seek Professional Help

Consult a healthcare provider for persistent nasal symptoms (e.g., obstruction, bleeding), unexplained weight loss, or skin lesions. Urgent care is needed for severe symptoms like difficulty breathing or signs of infection.

Tips for Medical Coders

Code C86.0 is specific to extranodal NK/T-cell lymphoma of nasal type. Document the site (e.g., nasal cavity, paranasal sinuses) and confirm EBV association if present. Differentiate from other lymphoma types (e.g., B-cell lymphomas) using pathology reports. Ensure specificity in coding extranodal sites and avoid miscoding as nodal lymphomas.